For immunochemical detection of the SARS-CoV/SARS-CoV-2 nucleocapsid protein
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

SARS-CoV/SARS-CoV-2 Nucleocapsid Protein Monoclonal Antibody (Clone 08)

Item No. 31984

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Synonyms
  • 2019-nCoV NP
  • 2019-nCoV Nucleocapsid Protein
  • 2019-nCoV Nucleoprotein
  • COVID-19 NP
  • COVID-19 Nucleocapsid Protein
  • COVID-19 Nucleoprotein
  • SARS-CoV-2 NP
  • SARS-CoV-2 Nucleoprotein
  • Severe Acute Respiratory Syndrome Coronavirus 2 Nucleocapsid Protein
Immunogen
Recombinant SARS-CoV nucleocapsid protein
Clone Designation
08
Formulation (Request formulation change)
50 or 100 µl of protein A-affinity purified monoclonal antibody
Storage Buffer
0.2 μm filtered solution in PBS
Host
Mouse
Isotype
IgG1
Applications
ELISA, FC, IHC-P, WB
Cross Reactivity
(+) Nucleocapsid protein(+) SARS-CoV-2 Delta (B.1.617) nucleocapsid protein (D377Y)(+) SARS-CoV-2 Delta (B.1.617) nucleocapsid protein (R230M, D377Y)(+) SARS-CoV-2 Delta (B.1.617.3) nucleocapsid protein (P67S, R203M, D377Y)(+) SARS-CoV-2 Alpha (B.1.1.7) nucleocapsid protein (R203K, G204R)(+) SARS-CoV-2 Alpha (B.1.1.7) nucleocapsid protein (I292T)(+) SARS-CoV-2 Alpha (B.1.1.7) nucleocapsid protein (D3L, R203K, G204R, S235F)(+) SARS-CoV-2 Alpha (B.1.1.7) nucleocapsid protein (D3L, S235F)(+) SARS-CoV-2 Alpha (B.1.1.7/B.1.237) nucleocapsid protein (S194L)(+) SARS-CoV-2 Alpha/Beta (B.1.1.7/B.1.351/A.2.2) nucleocapsid protein (P13L)(+) SARS-CoV-2 Beta (B.1.351/B.1.351.2/B.1.351.3/B.1.427/B.1.429) nucleocapsid protein (T205I)(+) SARS-CoV-2 Gamma (P.1/P.1.1/P.1.2) nucleocapsid protein (P80R)(+) SARS-CoV-2 Eta (B.1.525) nucleocapsid protein (A12G, T205I)
Species Reactivity
(+) SARS-CoV(+) SARS-CoV-2(+) SARS-CoV-2 Delta (B.1.617)(+) SARS-CoV-2 Delta (B.1.617.2)(+) SARS-CoV-2 Omicron (B.1.1.529)(+) SARS-CoV-2 Omicron (BA.2)(+) SARS-CoV-2 Omicron XE (BA.1 x BA.2)(+) SARS-CoV-2 Omicron (BA.4)(-) MERS-CoV(-) HCoV-229E(-) HCoV-NL63(-) HCoV-HKU1 (isolate N5)(-) HCoV-OC43
Shipping & Storage Information
Storage
-80°C
Shipping
Dry ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    50 µl

    $275

    Add

    100 µl

    $440

    Add
    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    Severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 nucleocapsid proteins are encoded by the N gene in SARS-CoV and SARS-CoV-2 RNA.1,2 SARS-CoV and SARS-CoV-2 are members of the Betacoronavirus genus of viruses that have approximately 79% sequence identity and share 27 T cell epitopes in common.3,4,5 The SARS-CoV-2 nucleocapsid protein has greater than 90% similarity to the SARS-CoV nucleocapsid protein and contains two unique B cell epitopes and two T cell epitopes that are structurally stable, non-allergenic, and induce production of IFN-γ.5,2 SARS-CoV and SARS-CoV-2 nucleocapsid proteins package the viral RNA into a helical ribonucleoprotein complex (RNP), which is a template for viral replication, and are integral for viral self-assembly and involved in regulation of the host cell cycle.6,2 SARS-CoV and SARS-CoV-2 are the causative agents of SARS and COVID-19, respectively, both of which are primarily respiratory illnesses characterized by fever, cough, and shortness of breath that can lead to life-threatening complications.4,7,8 Cayman's SARS-CoV/SARS-CoV-2 Nucleocapsid Protein Monoclonal Antibody (Clone 08) can be used for ELISA, flow cytometry (FC), immunohistochemistry-paraffin (IHC-P), and Western blot (WB) applications. The antibody recognizes wild-type and various mutant nucleocapsid proteins at 45.6 kDa from SARS-CoV, SARS-CoV-2, and several SARS-CoV-2 Alpha, Beta, Gamma, Delta, Eta, and Omicron subvariants.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Kandeel, M., Ibrahim, A., Fayez, M., et al. From SARS and MERS CoVs to SARS-CoV-2: Moving toward more biased codon usage in viral structural and nonstructural genes. J. Med. Virol. 92(6), 660-666 (2020).

    2. Kwarteng, A., Asiedu, E., Sakyi, S.A., et al. Targeting the SARS-CoV2 nucleocapsid protein for potential therapeutics using immuno-informatics and structure-based drug discovery techniques. Biomed. Pharmacother. 132, 110914 (2020).

    3. Lu, R., Zhao, X., Li, J., et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 395(10224), 565-574 (2020).

    4. Meo, S.A., Alhowikan, A.M., Al-Khlaiwi, T., et al. Novel coronavirus 2019-nCoV: Prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur. Rev. Med. Pharmacol. Sci. 24(4), 2012-2019 (2020).

    5. Ahmed, S.F., Quadeer, A.A., and McKay, M.R. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses 12(3), E254 (2020).

    6. Chang, C.-K., Hou, M.-H., Chang, C.-F., et al. The SARS coronavirus nucleocapsid protein – Forms and functions. Antiviral Res. 103, 39-50 (2014).

    7. Klok, F.A., Kruip, M.J.H.A., van der Meer, N.J.M., et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb. Res. 191, 145-147 (2020).

    8. Yang, F., Shi, S., Zhu, J., et al. Analysis of 92 deceased patients with COVID-19. J. Med. Virol. 92(11), 2511-2515 (2020).